The present invention relates to a process for preparing an orally administered pharmaceutical composition with colonic delivery, comprising at least one core and a coating layer, making it possible to obtain a pharmaceutical composition which exhibits uniform and reproducible dissolution and therefore likewise uniform and reproducible release of the active ingredient with low coefficients of variation, said process being characterized in that it comprises the following steps:
a) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 and at least one active ingredient intended to be delivered in the colon;
or
a′) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 then
b′) Dusting at least one active ingredient intended to be delivered in the colon onto the microgranules obtained after step a′);
c′) carrying out steps a′) and b′) alternately until the desired content of active ingredient has been obtained
and
d) Coating the microgranules obtained after step a) or c′) by spraying a composition comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 6, an anionic (meth)acrylate copolymer that is soluble at a pH greater than 7 and an anionic (meth)acrylate copolymer that is insoluble in an aqueous medium.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Computer software in the field of health; Downloadable computer software applications in the health sector; Artificial intelligence software for healthcare; Software as a medical device [SaMD], downloadable; Diagnostic computer software; Databases. Tools for medical diagnostics, Apparatus and instruments for use in medical diagnosis; Medical apparatus and instruments; Testing apparatus for medical purposes. Scientific and technological services and research and design relating thereto; Scientific laboratory services; Computer software design; Research and development of new products for others; Medical and pharmacological research services; Computer software research; Design and development of medical technology; Development of databases; Maintenance of databases; Conducting technical project studies; Project studies relating to software; Design and development of computer software in the field of health care; Design and development of medical diagnostic apparatus. Medical analysis services and Pharmacological analysis For diagnostic or therapeutic purposes; Medical and healthcare services; Telemedicine services; Medical diagnostic services; Medical evaluation services; Medical information; Providing information, in relation to the following fields: Medical services; Medical and therapeutical services, namely Medical and therapeutic services provided using digital tools.
3.
LOW-DOSAGE ORODISPERSIBLE OPIOID TABLET AND METHOD FOR PREPARING SAME
A low-dosage orodispersible opioid tablet including: 10 to 30% by weight of opioid granules, and 70% to 90% by weight of a mixture of compression excipients. The granules include 8 to 27% by weight of the opioid and 72% to 93% by weight of a mixture of diluent and binder. The mixture of compression excipients includes at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight of the tablet. Also, the method for preparing same.
The present invention relates to a process for preparing an orally administered pharmaceutical composition with colonic delivery, comprising at least one core and a coating layer, making it possible to obtain a pharmaceutical composition which exhibits uniform and reproducible dissolution and therefore likewise uniform and reproducible release of the active ingredient with low coefficients of variation, said process being characterized in that it comprises the following steps: a) Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 and at least one active ingredient intended to be delivered in the colon; or a') Spraying onto a neutral support an aqueous suspension comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 5.5 then b') Dusting at least one active ingredient intended to be delivered in the colon onto the microgranules obtained after step a'); c') carrying out steps a') and b') alternately until the desired content of active ingredient has been obtained, and d) Coating the microgranules obtained after step a) or c') by spraying a composition comprising at least one anionic (meth)acrylate copolymer that is soluble at a pH greater than 6, an anionic (meth)acrylate copolymer that is soluble at a pH greater than 7 and an anionic (meth)acrylate copolymer that is insoluble in an aqueous medium.
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Teaching; Training; Teaching; organising and conducting of conferences, seminars and training workshops, Organising and conducting webinars. Research and development of new technologies, in relation to the following fields: Medicine, Pharmacy; Research and development In the field of galenic innovation; Research and development In the field of medicated solutions; Medical and clinical studies (scientific research for medical purposes); Research and development, for others, of new products in the field of medicine and pharmaceuticals; Engineering services, in relation to the following fields: Medicine, Pharmacy; Chemical research; Chemical analytical examinations.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Pharmaceuticals; Medical preparations; Veterinary preparations; Sanitary preparations for medical purposes; Foodstuffs and dietetic substances for medical or veterinary purposes; Dietary supplements for animals; Dietary supplements for humans; Cannabis for medical purposes; Medicinal herbs; Medicinal infusions; Medicinal oils. Advertising; Business promotion; Marketing; Providing business information via a web site; Retail services and ON-LINE, in relation the following goods: Pharmaceutical preparations, Medical and veterinary preparations, Sanitary articles, All the aforesaid goods being based on cannabis eye patches for medical purposes.
9.
LOW-DOSAGE ORODISPERSIBLE OPIOID TABLET AND METHOD FOR PREPARING SAME
The invention relates to a low-dosage orodispersible opioid tablet comprising: - 10 to 30% by weight relative to the total weight of the tablet of opioid granules, and - 70% to 90% by weight relative to the total weight of the tablet of a mixture of compression excipients; the granules comprising 8 to 27% by weight relative to the weight of the granules of the opioid and 72% to 93% by weight relative to the weight of the granules of a mixture of diluent and binder, the mixture of compression excipients comprising at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight relative to the total weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight relative to the total weight of the tablet, and to the method for preparing same.
The invention relates to a low-dosage orodispersible opioid tablet comprising: - 10 to 30% by weight relative to the total weight of the tablet of opioid granules, and - 70% to 90% by weight relative to the total weight of the tablet of a mixture of compression excipients; the granules comprising 8 to 27% by weight relative to the weight of the granules of the opioid and 72% to 93% by weight relative to the weight of the granules of a mixture of diluent and binder, the mixture of compression excipients comprising at least one disintegrating agent, one diluting agent, one lubricating agent, one permeabilising agent, and optionally a sweetener, a flavouring and/or a colouring, the ratio between the lubricating agent and the permeabilising agent being greater than or equal to 1, the quantity of lubricating agent being 1 to 2% by weight relative to the total weight of the tablet, and the quantity of permeabilising agent being 0.5 to 5% by weight relative to the total weight of the tablet, and to the method for preparing same.
The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.
A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
15.
GRANULES OF AN ACTIVE SUBSTANCE WITH DOUBLE TASTE-MASKING TECHNIQUE, METHOD FOR THE PRODUCTION THEREOF, AND ORODISPERSIBLE TABLETS CONTAINING SAME
The invention relates to granules of an active substance with a double taste-masking technique, wherein the double taste-masking technique is achieved by a thermofusible compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and the mixtures thereof, and a soluble thermoplastic polymer with a pH lower than or equal to 5. The invention also relates to the method for producing said granules and to the orodispersible tablets containing said coated granules.
The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavoring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, excluding skincare preparations, acne medications, facial washes and goods in the nature of or for use as skincare preparations, acne medications or facial washes.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
The subject matter of the present invention is an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavouring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains, characterised in that said tablet is obtained by a method of compression moulding comprising the following steps; preparing the mixture of recipients by humidification, preferably in the form of grains, having a residual humidity or water level from 0.5% to 7%, preferably from 1% to 5%, and more preferably from 2% to 4%, preparing coated microcrystals or microgranules of the active ingredient, mixing the coated microcrystals or microgranules of the active ingredient and the wet mixture of excipients as prepared above, said mixture of excipients preferably being in the form of grains, potentially adding to the wet mixture for compression, as prepared above, excipients chosen from the group comprising a levelling agent, a lubricant, a flavouring agent, a sweetener, a dye, and mixtures thereof, compressing the mixture for compression prepared above in order to obtain a tablet, potentially drying the tablet thereby contained.
The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.
The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary products; dietetic
substances for medical use, food for babies; plasters,
materials for dressings; material for dental fillings and
dental impressions; disinfectants; products for destroying
vermin; fungicides, herbicides.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; Pharmaceutical products for the
treatment of all types of addictions and particularly
alcohol dependence or excessive alcohol consumption.
The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant.
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
39.
PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION OF A MEDICAMENT
The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.
The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
The invention relates to a novel oral pharmaceutical composition which is resistant to immediate discharge of the dose of active ingredient due to alcohol and which enables a single daily intake.
The invention relates to a novel oral pharmaceutical composition which is resistant to immediate discharge of the dose of active ingredient due to alcohol and which enables a single daily intake.
The present invention relates to an injectable pharmaceutical composition with gelling properties containing: -an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein the organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups. Its use as a vector for the release of active principles, as well as its process of preparation.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 9/00 - Medicinal preparations characterised by special physical form
46.
Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products, preparations, substances,
excipients, namely pharmaceutical products pertaining to the
pharmaceutical sector; veterinary preparations; sanitary
preparations for medical purposes; dietetic substances
adapted for medical use; disinfectants pertaining to the
pharmaceutical sector; chemical, biochemical and biological
products for medical and veterinary purposes; medical
solutions. Research and development of new technologies in the medical
and pharmaceutical fields; research and development in the
field of galenic innovation; research and development in the
field of medical solutions; medical and clinical studies
(scientific research services for medical purposes);
research and development (for others) in the medical and
pharmaceutical fields; engineering in the medical and
pharmaceutical fields; chemical research; chemical analyses.
The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in tablet form suitable for reducing blood concentration fluctuations of said opioid.
The invention relates to a Limus family immunosuppressive macrolide carrier/material formulation, as well as to an orally administered pharmaceutical composition containing same.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary preparations; excipients;
sanitary preparations for medical use; dietetic substances
for medical use; disinfectants; chemical, biochemical and
biological preparations, for medical and veterinary use. Research and development in the pharmaceutical industry,
particularly on technologies for the formation of in vivo
lipidic gel for the controlled release of an active
principle.
51.
PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE
The invention relates to an oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcoholic solution, or a neutral carrier rendered insoluble in water or an alcoholic solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the assembly comprises at least one coating containing at least one hydrophobic polymer.
The invention relates to an oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcoholic solution, or a neutral carrier rendered insoluble in water or an alcoholic solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the assembly comprises at least one coating containing at least one hydrophobic polymer.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary products; excipients; sanitary
products for medical purposes; dietetic substances adapted
for medical use; disinfectants; chemical, biochemical and
biological products, for medical and veterinary use. Research and development in the pharmaceutical field,
particularly with regard to tablets which are extremely
hard, difficult to crush, grind, cut or chew.
An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.
The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
The invention relates to a process for packaging products (5) in wells (2) in a plate (1) formed in a strip (4) and sealed by a cover film (6), comprising the following steps: a well-forming station (103) forms wells (2) in the travelling strip (4); a feeding system (107) fills each well (2) with a product (5) such as a pharmaceutical product in the form of a tablet or hard gelatin capsule; and a well-sealing station (109) seals the filled wells with the travelling cover film (6); the process being characterized in that it comprises, following well formation (2) but prior to each well being filled, the following steps: an incident laser beam marks the wells (2) on the strip (4); and the marked strip is cleaned. The invention also relates to a machine for implementing this process.
B65B 9/04 - Enclosing successive articles, or quantities of material, between opposed webs one or both webs being formed with pockets for the reception of the articles, or of the quantities of material
B65B 61/02 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for perforating, scoring, or applying code or date marks on material prior to packaging
B41M 5/24 - Ablative recording, e.g. by burning marksSpark recording
The present invention relates to an injectable pharmaceutical composition with gelling properties containing : - an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein : .cndot. R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and .cndot. R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
The present invention relates to an injectable pharmaceutical composition with gelling properties containing : - an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein : • R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and • R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation.
The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO″), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; excipients, namely, drug delivery agents consisting of compounds that facilitate the delivery a wide range of pharmaceuticals; veterinary pharmaceutical products, preparations and substances, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia, genitourinary conditions, vomiting, allergies, degenerative diseases and central nervous system diseases; sanitary pharmaceutical products for medical purposes, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases; dietetic substances adopted for medical use; all purpose disinfectants; chemical, biological and biochemical pharmaceutical products for medical and veterinary use, namely, pain relievers, anti-inflammatories, anti-infection agents, anti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditions, respiratory conditions, gastrointestinal conditions, hyper-cholesterolemia genitourinary conditions, vomiting, allergies, degenerative disease and central nervous system diseases Medical studies and clinical studies, namely, scientific research services for medical purposes; research and development of new products for third parties in the medical and pharmaceutical field; engineering services in the medical and pharmaceutical field; chemical research; chemical analyses
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products, preparations, substances;
excipients; veterinary products; sanitary products for
medical purposes; dietetic substances adapted for medical
use; disinfectants; chemical, biochemical and biological
products for medical and veterinary use. Medical studies and clinical studies (scientific research
services for medical purposes); research and development of
new products (for third parties) in the medical and
pharmaceutical field; engineering services in the medical
and pharmaceutical field; chemical research; chemical
analyses.
This invention pertains to an orally disintegrating multilayer tablet characterized in that it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl (meth) acrylate units and optionally a pore-forming agent.
The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
The present invention relates to a method of treatment of bacterial infections including administering an effective amount of an oral time -dependent antibiotic to a human or warm blooded animal.
Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.
Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa.
Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.
Water-insoluble matrix tablets which are capable of prolonged release of active principles liable to be diverted for drug addiction purposes, the said active principles being dispersed within a tabletting matrix composed of at least one excipient selected from the group consisting of pH-independent, water-insoluble delay polymers, inorganic excipients and mixtures thereof, and exhibiting a crush resistance of at least 4 MPa.
The invention concerns coated granules comprising (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, said pharmacological active principle being complexed by low cation-exchange resin comprising carboxylic acid groups (COO"), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of said components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
The invention concerns coated granules comprising (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, said pharmacological active principle being complexed by low cation-exchange resin comprising carboxylic acid groups (COO'), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of said components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
The present invention relates to a sublingual coated tablet and to the method for the preparation thereof . The tablet comprises a core devoid of a pharmaceutically active substance, and a coating comprising at least one active substance. The preferred active substance in an opioid analgesic.
Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products, preparations, substances;
excipients; veterinary products; sanitary products for
medical purposes; dietetic substances adapted for medical
use; disinfectants; chemical, biochemical and biological
products for medical and veterinary use. Medical studies and clinical studies (scientific research
services for medical purposes); research and development of
new products (for third parties) in the medical and
pharmaceutical field; engineering services in the medical
and pharmaceutical field; chemical research; chemical
analyses.
85.
Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary products, sanitary
preparations for medical use; dietetic substances adapted
for medical use, disinfectants; rapid disintegration
multiparticulate pills to be taken orally. Engineering services in the medical and pharmaceutical
fields; chemical research; chemical analyses; research and
development in the pharmaceutical field; research and
development in the pharmaceutical field concerning rapid
disintegration multiparticulate pills to be taken orally.
87.
USE OF GLYCEROL DIPALMITOSTEARATE FOR IMPROVING THE BIOAVAILABILITY OF PROTEIN ACTIVE INGREDIENTS IN SUBCUTANEOUS OR INTRAMUSCULAR INJECTABLE FORMULATIONS
The invention relates to the use of lipids as formulation agents for increasing the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations.
The invention relates to a method for preparing monodispersed biodegradable microspheres consisting in a) preparing an emulsion containing at least one polymeric phase and at least one aqueous phase at a viscosity ratio between the dispersed polymeric phase and the aqueous phase ranging from 0.12 to 10, b) exposing the thus obtained emulsion to a controlled laminar shear strength, c) removing a solvent from the polymeric phase and in d) isolating the thus obtained microspheres. The use of the prepared microspheres is also disclosed.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical and veterinary products; sanitary products
for medical purposes; dietetic substances adapted for
medical use; disinfectants. Engineering services in the medical and pharmaceutical
fields; chemical research; chemical analyses; research and
development in the pharmaceutical field.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products, preparations and substances; oral rapid disintegration multiparticular tablets which enable the administering of one or more substances, coated or not in order to mask their taste, without having to drink water at the same time. Research and development in the pharmaceutical field, in particular relating to oral rapid disintegration multiparticular tablets which enable the administering of one or more substances, coated or not in order to mask their taste, without having to drink water at the same time.
The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.
The invention relates to a composition comprising a monodispersed lipid phase which is dispersed in a continuous aqueous phase, wherein the lipid phase comprises at least one crystallizable lipid, at least one active ingredient and at least one compound including two chains of fatty acids and one glycol polyethylene chain. The invention also relates to a method for the preparation of said compositions via a simple monodispersed O/W or O/W/O double emulsion.
The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
[ Pharmaceutical and veterinary products, namely, chemical and pharmaceutical preparations enabling the delivery and administration of one or several active ingredients, specifically, on very slight soluble; dietetic foods adapted for medical use; disinfectants for hygienic purposes ] Engineering services in the medical and pharmaceutical fields; chemical research; chemical analyses; research and development in the pharmaceutical field
97.
PHARMACEUTICAL USE OF A COMPOSITION CONTAINING FENOFIBRATE
The invention is related to the use of a composition of fenofibrate containing micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, said composition containing an amount of fenofibrate greater than or equal to 60% by weight, for the preparation of a medicament for treating hypertriglyceridemias, hypercholesterolemias or hyperlipidemias while reducing the food effect on the bioävailability of fenofibrate. The invention is also related to an immediate release composition in the form of granules comprising : (a) a neutral core; (b) an active layer, wich surrounds the core; and (c)an outer layer; wherein said active layer comprises micronized fenofibrate, a surfactant and a binding cellulose derivative; and wherein said composition has a dissolution profile of less than 10% at 5 minutes and more than 80% at 20 minutes according to the European Pharmacopoeia in a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Research and development in the pharmaceutical and veterinary fields, in particular into coated microgranules containing an active ingredient, presented in the form of multiparticulate tablets which release the active ingredient they contain in a controlled way over a period of time.
